Anti-platelet therapy: Is it all over in peripheral artery disease?

Thrombosis and Haemostasis

Volumn 103, Issue 4, 2010, Pages 689-691

  Jaipersad, A S ^a,b   Silverman, Stanley H ^b   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PICOTAMIDE; PLACEBO;

ANKLE BRACHIAL INDEX; ARTERY DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL RESEARCH; CLINICAL TRIAL; DIABETES MELLITUS; EDITORIAL; HEART INFARCTION; HUMAN; INTERMITTENT CLAUDICATION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVASCULARIZATION; RISK REDUCTION; STENOSIS; STROKE; THROMBOCYTE;

ANKLE BRACHIAL INDEX; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; HUMANS; INTERMITTENT CLAUDICATION; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 77952030609     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-01-0053     Document Type: Editorial

References (32)

1. Bennett PC, Silverman S, Gill PS, et al. Ethnicity and peripheral artery disease. Q J Med 2009; 102: 3-16.
2. Anand S, Yusuf S, Xie C, et al. The Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral Anticoagulation and Antiplatelet Therapy and Peripheral Artery Disease. N Engl J Med 2007; 357: 217-227.
3. Steffen LM, Duprez DA, Boucher L, et al. Management of Peripheral Artery Disease. Diabetes Spectrum 2008; 21: 171-177.
4. Newman AB, Shemanski L, Manolio TA. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999; 19: 538-545. (Pubitemid 29135153)
5. Heald CL, Fowkes FG, Murray GD, et al. Ankle Brachial Index Collaboration: Risk of mortality and cardiovascular disease associated with ankle brachial index: systematic review. Atherosclerosis 2006; 189: 61-69.
6. Leng GC, Fowkes FGR, Lee AJ. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. Br Med J 1996; 313: 1440-1444.
7. Sodhi HS, Shrestha SK, Rauniyar R, et al. Prevalence of peripheral arterial disease by ankle-brachial index and its correlation with carotid intimal thickness and coronary risk factors in Nepalese population over the age of forty years. Kathmandu Univ Med J 2007; 5: 12-15. (Pubitemid 351507062)
8. Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentrations of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97: 425-428. (Pubitemid 28090212)
9. Smyth SS, Mcever RP, Weyrich AS, et al. Platelet function beyond hemostasis. Thromb Haemost 2009; 7: 1759-1766.
10. Dieter RS, Chu WW, Pacanowski JP, et al. The significance of lower extremity peripheral artery disease. Clin Cardiol 2002; 25: 3-10. (Pubitemid 34049124)
11. Holm T, Damås JK, Holven K, et al. CXC-chemokines in coronary artery disease: possible pathogenic role of interactions between oxidized lowdensity lipoprotein, platelets and peripheral blood mononuclear cells. Thromb Haemost 2003; 1: 257-262.
12. Falconer TM, Eikelboom JW, Hankey GJ, et al. Management of peripheral arterial disease in the elderly:focus on cilostazol. Clin Interv Aging 2008; 3: 17-23. (Pubitemid 351559800)
13. Davi G, Gresele P, Violi F. Diabetes mellitus, hypercholesterolemia, and hypertension but vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 1997; 96: 69-75.
14. Hohlfeld T, Zimmermann N, Weber AA, et al. Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis. Thromb Haemost 2007; 6: 166-173.
15. Blann AD, Tan KT, Tayebjee MH, et al. Soluble CD40L in peripheral artery disease. Relationship with disease severity, platelet markers and the effects of angioplasty. Thromb Haemost 2005; 93: 578-583.
16. Bennett PC, Silverman S, Gill PS, et al. Peripheral arterial disease and Virchow's triad. Thromb Haemost 2009; 101: 1032-1040.
17. Peace AJ, Tedesco AF, Foley DP, et al. Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease. Thromb Haemost 2008; 6: 2027-2034.
18. Ramcharan AS, Van Stralen KJ, Snoep JD, et al. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. Thromb Haemost 2008; 7: 514-520.
19. Basili S, Raparelli V, Vestri A, et al. Comparison of Efficacy of Antiplatelet Treatments for patients with claudication: A Meta-Analysis. Thromb Haemost 2010; 103: 766-773.
20. Murabito JM, D'Agostino RB, Silberhatz H, et al. Intermittent Claudication: a risk profile from the Framingham Heart Study. Circulation 1997; 96: 44-49.
21. Baigent C, Blackwell L, Collins R, et al. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860.
22. Berger JS, Krantz MJ, Kittelson JM, et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease. A Meta-analysis of randomized trials. J Am Med Assoc 2009; 301: 1909-1919.
23. Belch J, MacCuish A, Campbell I, et al. Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Br Med J 2008; 337: 1840.
24. st Century. J Am Med Assoc 2009; 301: 1927-1928.
25. CAPRIE Steering Committee. A Randomized, blinded trial of Clopidogrel vs Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet 1996; 348: 1329-1339.
26. Cacoub PP, Bhatt DL, Steg PG, et al. CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 2009; 30: 192-201.
27. Ogawa H, Nakayama M, Morimoto T, et al. Low- Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients with Type 2 Diabetes. A Randomized Controlled Trial. J Am Med Assoc 2008; 300: 2134-2141.
28. Lowry F. Aspirin for Asymptomatic Atherosclerosis (AAA) trialists. [Internet] European Society of Cardiology (ESC) 2009 Congress; Aug. 2009; Available from: http://www.theheart.org/article/996383.do
29. Dixon BS, DAC Study Group. The Effect of Dipyridamole plus Aspirin on Hemodialysis Graft Patency. N Engl J Med 2009; 360: 2191-2201.
30. Catalano M, Born G, Peto R. Critical Leg Ischaemia Prevention Study (CLIPS) Group. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med 2007; 261: 276-284.
31. Gresele P, Migliacci R. The peripheral arterial disease subgroup in the CHARISMA trial; does it tell us anything new? European Heart J 2009; 30: 131-132.
32. Bounameaux H. Intermittent claudication: how should we react to this symptom? Eur Heart J 2002; 23: 1002-1004.